Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | TPMT | P51580 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | LDHB | P07195 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.41 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21870 | 0.97 | KDM4E (0.55) | KDM4EL3MBTL1CYP3A4ACHETPMT | |
| SCHEMBL377596 | 0.97 | KDM4E (0.55) | KDM4EL3MBTL1CYP3A4ACHETPMT | |
| SCHEMBL6912704 | 0.95 | KDM4E (0.53) | KDM4EL3MBTL1CYP3A4ACHETPMT | |
| SCHEMBL6917032 | 0.95 | KDM4E (0.53) | KDM4EL3MBTL1CYP3A4ACHETPMT | |
| SCHEMBL6916700 | 0.95 | KDM4E (0.53) | KDM4EL3MBTL1CYP3A4ACHETPMT | |
| SCHEMBL17558193 | 0.95 | KDM4E (0.53) | KDM4EL3MBTL1CYP3A4ACHETPMT | |
| Hydrochloric Acid SCHEMBL5167636 | 0.95 | KDM4E (0.53) | KDM4EL3MBTL1CYP3A4ACHETPMT | |
| Bicarbonate SCHEMBL7975060 | 0.95 | KDM4E (0.53) | KDM4EL3MBTL1CYP3A4ACHETPMT | |
| SCHEMBL6915288 | 0.95 | KDM4E (0.53) | KDM4EL3MBTL1CYP3A4ACHETPMT | |
| SCHEMBL6916749 | 0.95 | KDM4E (0.53) | KDM4EL3MBTL1CYP3A4ACHETPMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0850241-B1 | IRIDIUM-DIPHOSPHINE COMPLEXES AND PROCESS FOR THE HYDROGENATION OF IMINES | NOVARTIS AG (CH) | 2001-08-29 | — | — | EP | disclosed |
| US-20010011085-A1 | 4-SUBSTITUTED CEPHEM DERIVATIVES AS ELASTASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 2001-08-02 | — | — | US | disclosed |
| US-6008393-A | A DITERTIARY DIPHOSPHINE WHICH IS BONDED TO A C2 TO C4 CARBON CHAIN, AND FORMS A 5 TO 7 MEMBERED RING WITH IRIDIUM HALIDE AND CONTAINING OXYACID ANION SUCH AS CARBOXYLIC ACID, SULFONIC ACID AND PHOSPHORIC ACID | NOVARTIS AG (CH) | 1999-12-28 | — | — | US | disclosed |
| EP-0850241-A1 | IRIDIUM-DIPHOSPHINE COMPLEXES AND PROCESS FOR THE HYDROGENATION OF IMINES | Novartis AG (CH) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997005150-A1 | IRIDIUM-DIPHOSPHINE COMPLEXES AND PROCESS FOR THE HYDROGENATION OF IMINES | NOVARTIS AG (CH) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011085-A1 | 4-SUBSTITUTED CEPHEM DERIVATIVES AS ELASTASE INHIBITORS | SERPINB1, ELANE, CTSE | KDM4E 490/4885L3MBTL1 1775/4885CYP3A4 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.